<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Epidemiological studies prove that incidence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is increasing </plain></SENT>
<SENT sid="1" pm="."><plain>The first line therapy of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is surgical resection of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> and elimination of regional and remote <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>THE AIM OF THE STUDY was to determine expression of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules CD134 and CD137 in the peripheral blood in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients, depending on clinical <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stage, size and invasion of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIAL AND METHODS: The study enrolled 72 patients with primary colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>An average patient age was 64.55 years </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage was assessed using two scales: Dukes: A and Astler-Coller scale </plain></SENT>
<SENT sid="6" pm="."><plain>Expression of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules was determined in the peripheral blood collected on the day of the procedure and 10 days after the procedure </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: An average activity of CD134 molecules (12.66%) was significantly higher than that of CD137 (6.26%) (p&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Clinical <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage was assessed on Dukes scale and was unrelated to CD134 activity, while activity of CD137 was related to clinical <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stage </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: CD137 activity is directly proportional to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> stage </plain></SENT>
<SENT sid="10" pm="."><plain>Surgical resection of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> results in increased CD134 and CD137 expression </plain></SENT>
<SENT sid="11" pm="."><plain>Long term studies, enrolling larger groups of patients, including their subdivision to colon and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, are required to utilize CD134 and CD137 in immune therapy of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>